Pharma News

RNA-based technology facilitates effective use for difficult-to-treat, large-gene diseases. Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size. The genes that are dysfunctional in muscular dystrophies are often extremely large, and current delivery methods can’t courier such substantial genetic loads into the body.

Sandoz the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Afqlir® (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to reference medicine Eylea®. Afqlir® is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD), aiming to prevent disease-related blindness.

National pharmaceuticals pricing authority asked pharmaceutical industries to reduce prices of anticancer medicines post declining custom duty to zero. The government reduced custom duty on three Anti-cancer medicines namely, Trastuzumab Deruxtecan, Osimertinib and Durvalumab.

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the microenvironment is too tumor-friendly. Researchers at the University of Basel and University Hospital Basel have now developed an immunotherapy that not only attacks the tumor—it also turns its microenvironment against it.

A new study from Karolinska Institutet shows that heart failure mortality has decreased in Sweden over the last 20 years. The study has been published in the European Journal of Heart Failure. 

A national study has shown that heart failure mortality has decreased in Sweden over the last two decades. Despite these improvements, the prognosis for heart failure patients remains worrying – 25 percent of those diagnosed in 2022 died within a year.